Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The study assesses PK and bioequivalence of the developed new drug VM‐1500FDC ‐ a fixed combination of three active substances: elsulfavirine (NNRTI), emtricitabine (NRTI) and tenofovir (NRTI) to Elpida® and Truvada® co‐administered. The combination is intended for once daily administration (1 tablet) for the treatment of HIV‐1 infection in adult patients. Thus, the purpose of this combination is to simplify the dosage regimen and improve patient compliance
Epistemonikos ID: 03553b8399a13322299e5222ecfe95e5cceefaf5
First added on: May 21, 2024